{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:24:47Z","timestamp":1791854687619,"version":"4.3.4"},"reference-count":72,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The last decades have seen great progress in the treatment of cold agglutinin disease (CAD). Comparative trials are lacking, and recommendations must be based mainly on nonrandomized trials and will be influenced by personal experience. Herein, current treatment options are reviewed and linked to 3 cases, each addressing specific aspects of therapy. Two major steps in CAD pathogenesis are identified, clonal B-cell lymphoproliferation and complement-mediated hemolysis, each of which constitutes a target of therapy. Although drug treatment is not always indicated, patients with symptomatic anemia or other bothersome symptoms should be treated. The importance of avoiding ineffective therapies is underscored. Corticosteroids should not be used to treat CAD. Studies on safety and efficacy of relevant drugs and combinations are briefly described. The author recommends that B cell\u2013directed approaches remain the first choice in most patients requiring treatment. The 4-cycle bendamustine plus rituximab combination is highly efficacious and sufficiently safe and induces durable responses in most patients, but the time to response can be many months. Rituximab monotherapy should be preferred in frail patients. The complement C1s inhibitor sutimlimab is an emerging option in the second line and may also find its place in the first line in specific situations.<\/jats:p>","DOI":"10.1182\/blood.2019003809","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T22:05:03Z","timestamp":1611266703000},"page":"1295-1303","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":131,"title":["How I treat cold agglutinin disease"],"prefix":"10.1182","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3425-4653","authenticated-orcid":false,"given":"Sigbj\u00f8rn","family":"Berentsen","sequence":"first","affiliation":[{"name":"Department of Research and Innovation, Haugesund Hospital, Helse Fonna Trust, Haugesund, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4","key":"2021031116253169900_B1","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood.2020005674","article-title":"Cold agglutinin disease revisited: a multinational, observational study of 232 patients","volume":"136","author":"Berentsen","year":"2020","journal-title":"Blood"},{"issue":"6281","key":"2021031116253169900_B2","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1136\/bmj.282.6281.2023","article-title":"Autoimmune haemolysis: an 18-year study of 865 cases referred to a regional transfusion centre","volume":"282","author":"Sokol","year":"1981","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"3","key":"2021031116253169900_B3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.blre.2012.01.002","article-title":"Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia","volume":"26","author":"Berentsen","year":"2012","journal-title":"Blood Rev"},{"key":"2021031116253169900_B4","doi-asserted-by":"crossref","first-page":"100648","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting","volume":"41","author":"J\u00e4ger","year":"2020","journal-title":"Blood Rev"},{"issue":"12","key":"2021031116253169900_B5","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/bloodadvances.2019000036","article-title":"Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment","volume":"3","author":"Hill","year":"2019","journal-title":"Blood Adv"},{"issue":"3","key":"2021031116253169900_B6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3324\/haematol.2013.091702","article-title":"Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma","volume":"99","author":"Randen","year":"2014","journal-title":"Haematologica"},{"issue":"11-12","key":"2021031116253169900_B7","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s00508-014-0547-z","article-title":"Cold antibody autoimmune hemolytic anemia and lymphoproliferative disorders: a retrospective study of 20 patients including clinical, hematological, and molecular findings","volume":"126","author":"Arthold","year":"2014","journal-title":"Wien Klin Wochenschr"},{"issue":"6","key":"2021031116253169900_B8","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1182\/bloodadvances.2020001608","article-title":"Cold agglutinin-associated B-cell lymphoproliferative disease shows highly recurrent gains of chromosome 3 and 12 or 18","volume":"4","author":"Ma\u0142ecka","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2021031116253169900_B9","first-page":"27","article-title":"The cold hemagglutinin disease","volume":"3","author":"Schubothe","year":"1966","journal-title":"Semin Hematol"},{"issue":"4","key":"2021031116253169900_B10","first-page":"460","article-title":"Primary chronic cold agglutinin disease: a population based clinical study of 86 patients","volume":"91","author":"Berentsen","year":"2006","journal-title":"Haematologica"},{"issue":"7","key":"2021031116253169900_B11","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood-2013-02-474437","article-title":"Cold agglutinin disease","volume":"122","author":"Swiecicki","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2021031116253169900_B12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/10428190500286481","article-title":"Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients","volume":"47","author":"Sch\u00f6llkopf","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2021031116253169900_B13","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N Engl J Med"},{"key":"2021031116253169900_B14","first-page":"e184","article-title":"Cold agglutinin disease is a phenotypically distinct clonal B-cell disorder. 15 International Myeloma Workshop, Rome, Italy: Sept 23-26, 2015","volume":"15","author":"de Tute","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"2021031116253169900_B15","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bjh.15063","article-title":"Frequent somatic mutations of KMT2D (MLL2) and CARD11 genes in primary cold agglutinin disease","volume":"183","author":"Ma\u0142ecka","year":"2018","journal-title":"Br J Haematol"},{"issue":"7","key":"2021031116253169900_B16","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.4049\/jimmunol.149.7.2337","article-title":"VH restriction among human cold agglutinins. The VH4-21 gene segment is required to encode anti-I and anti-i specificities","volume":"149","author":"Pascual","year":"1992","journal-title":"J Immunol"},{"issue":"9","key":"2021031116253169900_B17","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.3324\/haematol.2016.146126","article-title":"Immunoglobulin heavy and light chain gene features are correlated with primary cold agglutinin disease onset and activity","volume":"101","author":"Ma\u0142ecka","year":"2016","journal-title":"Haematologica"},{"issue":"2","key":"2021031116253169900_B18","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2141.1995.tb05315.x","article-title":"Trisomy 3 is a consistent chromosome change in malignant lymphoproliferative disorders preceded by cold agglutinin disease","volume":"91","author":"Michaux","year":"1995","journal-title":"Br J Haematol"},{"key":"2021031116253169900_B19","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.3389\/fonc.2019.01435","article-title":"Autoimmune cytopenias in chronic lymphocytic leukemia: focus on molecular aspects","volume":"9","author":"Fattizzo","year":"2020","journal-title":"Front Oncol"},{"issue":"3","key":"2021031116253169900_B20","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1600-0609.1965.tb01303.x","article-title":"Exclusive occurrence of K chains in isolated cold haemagglutinins","volume":"2","author":"Harboe","year":"1965","journal-title":"Scand J Haematol"},{"key":"2021031116253169900_B21","first-page":"240","volume-title":"The Haemolytic Anaemias","author":"Dacie","year":"1992"},{"issue":"26","key":"2021031116253169900_B22","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1182\/blood-2014-02-556027","article-title":"TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins","volume":"123","author":"Shi","year":"2014","journal-title":"Blood"},{"key":"2021031116253169900_B23","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3389\/fimmu.2020.00590","article-title":"New insights in the pathogenesis and therapy of cold agglutinin-mediated autoimmune hemolytic anemia","volume":"11","author":"Berentsen","year":"2020","journal-title":"Front Immunol"},{"key":"2021031116253169900_B24","doi-asserted-by":"crossref","first-page":"2040620719873321","DOI":"10.1177\/2040620719873321","article-title":"Novel insights into the treatment of complement-mediated hemolytic anemias","volume":"10","author":"Berentsen","year":"2019","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"2021031116253169900_B25","first-page":"66","article-title":"Immunopathologic and clinical features of hemolytic anemia due to cold agglutinins","volume":"28","author":"Nydegger","year":"1991","journal-title":"Semin Hematol"},{"issue":"19","key":"2021031116253169900_B26","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1182\/bloodadvances.2018024190","article-title":"Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial","volume":"2","author":"R\u00f6th","year":"2018","journal-title":"Blood Adv"},{"issue":"2","key":"2021031116253169900_B27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1600-0609.1998.tb01004.x","article-title":"Paradoxical haemolysis in a patient with cold agglutinin disease","volume":"60","author":"Ulvestad","year":"1998","journal-title":"Eur J Haematol"},{"issue":"1-2","key":"2021031116253169900_B28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1046\/j.1365-3083.2001.00960.x","article-title":"Acute phase haemolysis in chronic cold agglutinin disease","volume":"54","author":"Ulvestad","year":"2001","journal-title":"Scand J Immunol"},{"key":"2021031116253169900_B29","article-title":"Inhibition of complement C1s with sutimlimab in patients with cold agglutinin disease (CAD): results from the phase 3 Cardinal study [abstract].","volume-title":"Blood","author":"R\u00f6th"},{"issue":"8","key":"2021031116253169900_B30","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood-2003-10-3597","article-title":"Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients","volume":"103","author":"Berentsen","year":"2004","journal-title":"Blood"},{"key":"2021031116253169900_B31","first-page":"232","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017","edition":"4th ed"},{"issue":"3","key":"2021031116253169900_B32","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjh.14478","article-title":"The diagnosis and management of primary autoimmune haemolytic anaemia","volume":"176","author":"Hill","year":"2017","journal-title":"Br J Haematol"},{"issue":"3","key":"2021031116253169900_B33","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/bjh.15109","article-title":"How I manage patients with cold agglutinin disease","volume":"181","author":"Berentsen","year":"2018","journal-title":"Br J Haematol"},{"key":"2021031116253169900_B34","article-title":"Efficacy of recombinant erythropoietin in autoimmune haemolytic anaemia: a multicentre international study [published online ahead of print 30 April 2020]","author":"Fattizzo","journal-title":"Haematologica"},{"issue":"19","key":"2021031116253169900_B35","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1182\/blood-2014-06-583021","article-title":"Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients","volume":"124","author":"Barcellini","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2021031116253169900_B36","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.3324\/haematol.2015.128991","article-title":"Complement deposition in autoimmune hemolytic anemia is a footprint for difficult-to-detect IgM autoantibodies","volume":"100","author":"Meulenbroek","year":"2015","journal-title":"Haematologica"},{"issue":"5","key":"2021031116253169900_B37","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1699-0463.1997.tb00581.x","article-title":"Chronic cold agglutinin disease of the \u201cidiopathic\u201d type is a premalignant or low-grade malignant lymphoproliferative disease","volume":"105","author":"Berentsen","year":"1997","journal-title":"APMIS"},{"key":"2021031116253169900_B38","first-page":"210","volume-title":"The Haemolytic Anaemias","author":"Dacie","year":"1992"},{"issue":"3","key":"2021031116253169900_B39","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood.V56.3.409.409","article-title":"The variability of hemolysis in the cold agglutinin syndrome","volume":"56","author":"Rosse","year":"1980","journal-title":"Blood"},{"issue":"4","key":"2021031116253169900_B40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1600-0609.1999.tb01887.x","article-title":"Clinical immunology of chronic cold agglutinin disease","volume":"63","author":"Ulvestad","year":"1999","journal-title":"Eur J Haematol"},{"key":"2021031116253169900_B41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2147\/JBM.S177621","article-title":"Cold agglutinin disease: current challenges and future prospects","volume":"10","author":"Berentsen","year":"2019","journal-title":"J Blood Med"},{"key":"2021031116253169900_B42","first-page":"502","volume-title":"The Haemolytic Anaemias","author":"Dacie","year":"1992"},{"issue":"4","key":"2021031116253169900_B43","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2017-04-778175","article-title":"Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial","volume":"130","author":"Berentsen","year":"2017","journal-title":"Blood"},{"issue":"13","key":"2021031116253169900_B44","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/bloodadvances.2017004390","article-title":"Cold agglutinin disease burden: a longitudinal analysis of anemia, medications, transfusions, and health care utilization","volume":"1","author":"Mullins","year":"2017","journal-title":"Blood Adv"},{"key":"2021031116253169900_B45","article-title":"Clinical characteristics, treatment patterns, and thromboembolic risk of patients with cold agglutinin dosease (CAD) in Japan","author":"Kamesaki"},{"issue":"6","key":"2021031116253169900_B46","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1179\/102453309X12473408860262","article-title":"Diabetes mellitus is associated with high early-mortality and poor prognosis in patients with autoimmune hemolytic anemia","volume":"14","author":"Nakasone","year":"2009","journal-title":"Hematology"},{"issue":"4","key":"2021031116253169900_B47","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1172\/JCI108547","article-title":"The role of complement in the clearance of cold agglutinin-sensitized erythrocytes in man","volume":"58","author":"Jaffe","year":"1976","journal-title":"J Clin Invest"},{"issue":"2","key":"2021031116253169900_B48","doi-asserted-by":"crossref","first-page":"238","DOI":"10.7326\/0003-4819-106-2-238","article-title":"Cold hemagglutinin disease associated with IgG cold-reactive antibody","volume":"106","author":"Silberstein","year":"1987","journal-title":"Ann Intern Med"},{"issue":"4","key":"2021031116253169900_B49","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/rth2.12333","article-title":"Increased risk of thrombotic events in cold agglutinin disease: a 10-year retrospective analysis","volume":"4","author":"Broome","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"20","key":"2021031116253169900_B50","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/bloodadvances.2019000476","article-title":"Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease","volume":"3","author":"Bylsma","year":"2019","journal-title":"Blood Adv"},{"issue":"10","key":"2021031116253169900_B51","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1080\/1744666X.2018.1521722","article-title":"Current and emerging treatment options for autoimmune hemolytic anemia","volume":"14","author":"Barcellini","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"issue":"17","key":"2021031116253169900_B52","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1182\/blood-2010-06-288647","article-title":"High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease","volume":"116","author":"Berentsen","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2021031116253169900_B53","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1182\/blood-2018-03-835413","article-title":"Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study","volume":"132","author":"Rossi","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2021031116253169900_B54","first-page":"268","article-title":"Delayed response to fludarabine in lymphoplasmacytic lymphoma\/Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"90","author":"Del Giudice","year":"2005","journal-title":"Haematologica"},{"issue":"11","key":"2021031116253169900_B55","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.4049\/jimmunol.1202317","article-title":"Pathogenic long-lived plasma cells and their survival niches in autoimmunity, malignancy, and allergy","volume":"189","author":"Winter","year":"2012","journal-title":"J Immunol"},{"issue":"4","key":"2021031116253169900_B56","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.pathol.2017.02.004","article-title":"Role of plasma cells in Waldenstr\u00f6m macroglobulinaemia","volume":"49","author":"El-Ayoubi","year":"2017","journal-title":"Pathology"},{"issue":"16","key":"2021031116253169900_B57","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1182\/blood-2009-01-196329","article-title":"Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease","volume":"113","author":"R\u00f6th","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2021031116253169900_B58","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1182\/blood-2012-11-467209","article-title":"C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia","volume":"121","author":"Wouters","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2021031116253169900_B59","doi-asserted-by":"crossref","first-page":"30","DOI":"10.14740\/jh242w","article-title":"A novel approach for treatment of cold agglutinin syndrome-related severe hemolysis","volume":"5","author":"Tesfaye","year":"2016","journal-title":"J Hematol"},{"issue":"9","key":"2021031116253169900_B60","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2018-06-856930","article-title":"Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial","volume":"133","author":"J\u00e4ger","year":"2019","journal-title":"Blood"},{"issue":"13","key":"2021031116253169900_B61","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/blood-2013-11-536573","article-title":"Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria [published correction appears in Blood. 2017;129(15):2205]","volume":"123","author":"Risitano","year":"2014","journal-title":"Blood"},{"issue":"22","key":"2021031116253169900_B62","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1251.1251","article-title":"APL-2, a complement C3 inhibitor for the potential treatment of paroxysmal nocturnal hemoglobinuria (PNH): phase I data from two completed studies in healthy volunteers [abstract]","volume":"128","author":"Grossi","year":"2016","journal-title":"Blood."},{"issue":"suppl 1","key":"2021031116253169900_B63","article-title":"Inhibition of C3 with APL-2 results in normalisation of markers of intravascular and extravascular hemolysis in patients with autoimmune hemolytic anemia (AIHA) [abstract]","volume":"132","author":"Grossi","year":"2018","journal-title":"Blood."},{"issue":"15","key":"2021031116253169900_B64","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"16","key":"2021031116253169900_B65","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/blood-2018-08-867499","article-title":"Parsaclisib, a potent and highly selective PI3K\u03b4 inhibitor, in patients with relapsed or refractory B-cell malignancies","volume":"133","author":"Forero-Torres","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2021031116253169900_B66","article-title":"Effective treatment of cold agglutinin disease\/cold agglutinin syndrome with ibrutinib: an international case series [abstract]","volume":"136","author":"Jalink","year":"2020","journal-title":"Blood."},{"issue":"3","key":"2021031116253169900_B67","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol"},{"issue":"19","key":"2021031116253169900_B68","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1182\/bloodadvances.2018020883","article-title":"Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation","volume":"2","author":"Schuetz","year":"2018","journal-title":"Blood Adv"},{"key":"2021031116253169900_B69","article-title":"Daratumumab for disabling cold agglutinin disease refractory to B-cell directed therapy [published online ahead of print 11 July 2020]","author":"Tomkins","journal-title":"Am J Hematol"},{"issue":"6","key":"2021031116253169900_B70","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1182\/bloodadvances.2019001321","article-title":"Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program","volume":"4","author":"Gelbenegger","year":"2020","journal-title":"Blood Adv"},{"key":"2021031116253169900_B71","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1265.1265","article-title":"ANX005, an inhibitory antibody against C1q, blocks complement activation triggered by cold agglutinins in human disease [abstract]","volume":"128","author":"Gertz","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2021031116253169900_bib72","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2019-01-894303","article-title":"Cold agglutinins: fending off the attack","volume":"133","author":"Berentsen","year":"2019","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/10\/1295\/1802093\/bloodbld2019003809c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/10\/1295\/1802093\/bloodbld2019003809c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T18:02:56Z","timestamp":1697652176000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/10\/1295\/475028\/How-I-treat-cold-agglutinin-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,11]]},"references-count":72,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,3,11]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019003809","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,11]]}}}